Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal Blood Flow and Autoregulation as Biomarkers for Early Glaucoma
NCT05344274Phase 4Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2022
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by University of Maryland, Baltimore. Primary endpoint: Autoregulation of retinal blood flow at 3 years. Started May 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05344274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344274.